

ADDITIONAL METHODOLOGICAL DETAILS

The processing device used was TEG[®] 5000 Thrombelastograph[®] Hemostasis Analyzer (manufactured by Haemonetics). Citrated Kaolin was the activating agent used to initiate clotting cascade on all samples and specialized laboratory technicians ran the tests. As our goal was to evaluate factor activity in the setting of already administered medications (heparin/lovenox), heparinase was only used in the rare instances when background patient coagulation activity would lead to changes in treatment. In addition to the standard TEG profile, platelet mapping (PM) was added to better analyze platelet activity and appropriately tailor treatment interventions with anti-platelet medications. TEG-PM was used to specifically assess activation of the platelet's COX1 (MA-AA) and P2Y12 pathways (MA-ADP).